Cover Image
市場調查報告書

全球搭配診斷市場:各技術(聚合酵素鏈鎖反應,in-situ雜合反應,免疫組織化學),用途(乳癌,肺癌),終端用戶(製藥公司,參考實驗室)市場趨勢和預測

Companion Diagnostics Market byTechnology (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry), Application (Breast, Lung cancer), & by End-user (Pharmaceutical Companies, Reference Lab)] - Global Trends & Forecasts to 2019

出版商 MarketsandMarkets 商品編碼 312600
出版日期 內容資訊 英文 137 Pages
訂單完成後即時交付
價格
Back to Top
全球搭配診斷市場:各技術(聚合酵素鏈鎖反應,in-situ雜合反應,免疫組織化學),用途(乳癌,肺癌),終端用戶(製藥公司,參考實驗室)市場趨勢和預測 Companion Diagnostics Market byTechnology (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry), Application (Breast, Lung cancer), & by End-user (Pharmaceutical Companies, Reference Lab)] - Global Trends & Forecasts to 2019
出版日期: 2014年09月08日 內容資訊: 英文 137 Pages
簡介

搭配診斷的市場,由於癌症等的個體化治療和量身訂做的醫藥品的需求高漲、製藥公司和生物科技企業、參考實驗室等終端用戶引進搭配診斷試驗等要素的推動,而繼續成長,促使美國食品藥物管理局(FDA)和歐洲藥品管理局(EMA)等也在醫藥品開發的早期階段開發搭配診斷試驗。另一方面,依地區而有很大不同的醫療費給付標準、保險申請規則、技術評估手續、未核準的自體調整實驗(LDT)等,妨礙成長的要素也不少。可是搭配診斷,預計應用於神經學的疾病和感染疾病等,次世代定序(NGS)為基礎的搭配診斷的實用化和生物資訊學領域的發展等也可預期,今後也將踏實成長。全球搭配診斷市場,預計從2014年的31億3,690萬美元至2019年擴大到87億3,070萬美元,其間的年複合成長率(CAGR)為22.7%。

本報告以全球搭配診斷市場為焦點,提供產業的趨勢等揭示、各用途、技術、終端用戶、地區的市場分析,也網羅競爭情形和主要企業簡介。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 主要分析結果

第5章 市場概要

  • 簡介
  • 演進
  • 市場區隔
  • 市場力學
    • 成長推動因素
    • 成長阻礙因素
    • 商機
    • 促進NGS等市場成長的各種新技術

第6章 產業的趨勢

  • 波特的五力分析
  • 策略性基準

第7章 各用途的市場

  • 簡介
  • 乳癌
  • 肺癌
  • 結腸直腸癌
  • 黑色素瘤
  • 胃癌
  • 其他的適應症(前列腺癌、卵巢癌、白血病、感染疾病、神經學的疾病)

第8章 各技術的市場

  • 簡介
  • 聚合酵素鏈鎖反應(PCR)
  • in-situ雜合反應(ISH)
  • 免疫組織化學(IHC)
  • 其他技術(NGS、多重化驗、細胞免疫試驗、單株抗體)

第9章 各終端用戶的市場

  • 簡介
  • 製藥公司
  • 參考實驗室
  • 其他(醫藥品臨床研究委外機構(CRO)、醫生、醫院、大學醫療中心)

第10章 各地區的市場

  • 簡介
  • 北美
  • 歐洲
  • 亞洲
  • 其他的地區

第11章 競爭情形

  • 概要
  • 協定、聯盟與合作
  • 合併和收購
  • 新產品發表
  • 產業擴大

第12章 主要企業簡介

  • 簡介
  • Abbott Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Biomerieux
  • Biogenex Laboratories
  • Danaher Corporation
  • Ge Healthcare
  • Myriad Genetics, Inc.
  • Qiagen N.V.
  • Roche Diagnostics
  • Thermo Fisher Scientific, Inc.

圖表清單

目錄
Product Code: BT 2698

The global companion diagnostics market is expected to grow at a CAGR of 22.7% from 2014 to 2019. Factors such as rising need for personalized medicine in cancer treatment, growing adoption of companion diagnostics by the pharmaceutical industry, support from regulatory authorities, and emerging technologies such as next-generation sequencing (NGS) are expected to boost the global companion diagnostics market.

Among technologies, PCR is the most preferred test in the companion diagnostics market, which accounted for a share of 65.5% in 2014. This large share can be attributed to its ease of use, better results, faster turnaround time, and cost-effective solutions. The companion diagnostics market is expected to gain a larger market share in neurology and new oncology applications (leukemia, prostate cancer, and ovarian cancer) due to its efficient detection of biomarkers. Moreover, with the advancement in the bioinformatics field, NGS-based tests have the capability to target multiple genomes simultaneously and are likely to take over the existing technologies in the companion diagnostics market. The need for personalized medicine is increasing and it has gained importance in the research and medical centers, hospitals, and CROs. In the coming years, Asia is expected to be the key growth area in this market.

However, growth of this market is hampered by the non-validated home brew tests that account for a large market share due to its low costs and minimal approval procedures. Moreover, uncertain reimbursement and coverage policies restrict the growth of the global companion diagnostic market, thus limiting the commercialization process.

Reasons to Buy the Report

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner a greater market share. Firms purchasing the report can use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product portfolios of the top players in the companion diagnostics market. The report analyzes the companion diagnostics market by technology, application, end-user, and geography
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the companion diagnostics market
  • Competitive Assessment: In-depth assessment of the market strategies, geographical and business segments, and product portfolios of the leading players in the companion diagnostics market
  • Market Development: Comprehensive information about the emerging markets. The report analyzes the market for various companion diagnostics tests/kits across geographies
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the companion diagnostics market

Table of Contents

1 Introduction

  • 1.1 Objectives Of The Study
  • 1.2 Markets Covered
  • 1.3 Stakeholders
  • 1.4 Market Scope

2 Research Methodology

  • 2.1 Market Size Estimation
  • 2.2 Market Share Estimation
    • 2.2.1 Key Data Taken From Secondary Sources
    • 2.2.2 Key Data From Primary Sources
    • 2.2.3 Key Industry Insights
    • 2.2.4 Assumptions

3 Executive Summary

4 Premium Insights

5 Market Overview

  • 5.1 Introduction
  • 5.2 Evolution
  • 5.3 Market Segmentation
    • 5.3.1 Companion Diagnostics Market
  • 5.4 Market Dynamics
    • 5.4.1 Market Drivers
      • 5.4.1.1 Regulatory Bodies Encouraging Implementation Of Companion Diagnostics
      • 5.4.1.2 Rising Demand For Targeted Cancer Treatment & Tailored Drugs Ensure Robust Market Growth In Companion Diagnostic Tests
      • 5.4.1.3 Growing Adoption Of Companion Diagnostics By Pharmaceutical Companies & Reference Laboratories To Boost The Market
    • 5.4.2 Market Restraints
      • 5.4.2.1 Reimbursement Scenarios In Different Regions Hamper The Companion Diagnostic Market Growth
      • 5.4.2.2 Laboratory Developed Tests (Home Brew Tests) Affect Adoption Of Companion Diagnostic Tests
    • 5.4.3 Market Opportunities
    • 5.4.3.1 Emerging Technologies Such As Next-Generation Sequencing (NGS) Likely To Stimulate The Market
      • 5.4.3.2 Increasing Scope For Companion Diagnostics In Other Cancer Indications (Ovarian, Leukemia, Prostate) & Neurology

6 Industry Trends

  • 6.1 Porter's Five Forces Analysis
    • 6.1.1 Threat From New Entrants
    • 6.1.2 Threat From Substitutes
    • 6.1.3 Bargaining Power Of Suppliers
    • 6.1.4 Bargaining Power Of Buyers
    • 6.1.5 Intensity Of Competitive Rivalry
  • 6.2 Strategic Benchmarking

7 Global Companion Diagnostics Market, By Applications

  • 7.1 Introduction
  • 7.2 Breast Cancer
  • 7.3 Lung Cancer
  • 7.4 Colorectal Cancer
  • 7.5 Melanoma
  • 7.6 Gastric Cancer
  • 7.7 Other Indications (Prostate, Ovarian, Leukemia, Infectious Disease & Neurology)

8 Global Companion Diagnostics Market, By Technology

  • 8.1 Introduction
  • 8.2 Polymerase Chain Reaction (PCR)
  • 8.3 In Situ Hybridization (ISH)
  • 8.4 Immunohistochemistry (IHC)
  • 8.5 Other Technologies (NGS,Multiplex Assay, Cellular Immune Testing, Mab)

9 Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical Companies
    • 9.2.1 Companion Diagnostics Help To Reduce Cost & Aid In Faster Fda Clearance
    • 9.2.2 Accurate Identification & Recruitment Of Participants In Clinical Trials
    • 9.2.3 Pharmaceutical Companies Are Undergoing Partnerships & Collaborations With Companion Diagnostics Manufacturers
    • 9.2.4 Breast Cancer & Non-Small Cell Lung Cancer (NSCLC) Are The Major Focus Areas For Pharmaceutical Companies
    • 9.2.5 Payors Have Identified The Benefits Of Companion Diagnostics In Near Future
    • 9.2.6 Regulatory Agencies Encourage Drug Makers To Adopt Companion Diagnostics Test
  • 9.3 Reference Lab
    • 9.3.1 Importance Of Reference Laboratries In Global Market
  • 9.4 Others (Cro, Physicians, Hospitals & Academic Medical Centers)

10 Global Companion Diagnostics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 Key Players Focusing On Companion Diagnostics For Breast And Lung Cancer
    • 10.2.2 Fda Initiatives In The U.S. To Encourage Significant Adoption Of Companion Diagnostics
    • 10.2.3 Adoption Of Pay-For-Performance Program Stimulates Payors To Reimburse For Companion Diagnostic Tests
    • 10.2.4 Focus On Personalized Medicine Is A Major Driver For Companion Diagnostics
  • 10.3 Europe
    • 10.3.1 Ema Supports The Development Of Companion Diagnostic Tests
    • 10.3.2 Rising Incidence Of Breast Cancer In Europe
    • 10.3.3 Fragmented Reimbursement Policy In Europe Hindering In Vitro Diagnostic Manufacturers From Investing In Companion Diagnostic Tests
  • 10.4 Asia
  • 10.5 Rest Of The W0rld

11 Competitive Landscape

  • 11.1 Overview
  • 11.2 Agreements, Partnerships & Collaborations
  • 11.3 Merger And Acquisitions
  • 11.4 New Product Launches
  • 11.5 Expansion

12 Company Profiles

  • 12.1 Introduction
  • 12.2 Abbott Laboratories, Inc.
  • 12.3 Agilent Technologies, Inc.
  • 12.4 Biomérieux
  • 12.5 Biogenex Laboratories
  • 12.6 Danaher Corporation
  • 12.7 Ge Healthcare
  • 12.8 Myriad Genetics, Inc.
  • 12.9 Qiagen N.V.
  • 12.10 Roche Diagnostics
  • 12.11 Thermo Fisher Scientific, Inc.

List of Tables

  • Table 1 Increasing Need For Targeted Treatment In Oncology Is Propelling The Global arket
  • Table 2 Reimbursement Issues Hamper Growth Of Market
  • Table 3 Advanced Technologies Likely To Stimulate Market Growth
  • Table 1 Global Market, By Applications, 2012-2019 ($Million) 44
  • Table 2 Breast Cancer Companion Diagnostics Market, By Geography, 2012-2019 ($Million) 45
  • Table 3 Lung Cancer Companion Diagnostics Market, By Geography, 2012-2019 ($Million) 49
  • Table 4 Colorectal Cancer Companion Diagnostics Market, By Geography, 2012-2019 ($Million)
  • Table 5 Melanoma Companion Diagnostics Market, By Geography, 2012-2019 ($Million) 52
  • Table 6 Gastric Cancer Companion Diagnostics Market, By Geography, 2012-2019 ($Million) 53
  • Table 7 Other Indications Companion Diagnostics Market, By Geography, 2012-2019 ($Million) 54
  • Table 8 Global Companion Diagnostics Market Size, By Technology, 2012-2019 ($Million) 57
  • Table 9 Market Size For Polymerase Chain Reaction, By Geography, 2012-2019 ($Million) 58
  • Table 10 Market Size For In Situ Hybridization, By Geography, 2012-2019 ($Million) 60
  • Table 11 Market Size For Immunohistochemistry, By Geography, 2012-2019 ($Million) 61
  • Table 12 Market Size For Other Technologies, By Geography, 2012-2019 ($Million) 63
  • Table 13 Global Companion Diagnostics Market, By End-Users, 2014-2019 ($Million) 66
  • Table 14 Pharmaceutical Companies Companion Diagnostics Market, By Geography, 2014-2019 ($Million) 68
  • Table 15 Reference Laboratories Companion Diagnostics Market, By Geography, 2014-2019 ($Million) 71
  • Table 16 Other End Users Companion Diagnostics Market, By Geography, 2014-2019 ($Million) 73
  • Table 17 Companion Diagnostics Market Size, By Geography, 2012-2019 ($Million) 76
  • Table 18 North America: Companion Diagnostics Market Size, By Application, 2012-2019 ($Million)
  • Table 19 North America: Market Size, By End User, 2012-2019 ($Million) 82
  • Table 20 North America: Market Size For Pharmaceutical Companies, By Application, 2012-2019 ($Million)
  • Table 21 North America: Market Size For Reference Laboratories, By Application, 2012-2019 ($Million)
  • Table 22 North America: Market Size For Other End Users, By Application, 2012-2019 ($Million)
  • Table 23 North America: Market Size, By Technology, 2012-2019 ($Million)
  • Table 24 North America: Market Size For Pharmaceutical Companies, By Technology, 2012-2019 ($Million)
  • Table 25 North America: Market Size For Reference Laboratories, By Technology, 2012-2019 ($Million)
  • Table 26 North America: Market Size For Other End Users, By Technology, 2012-2019 ($Million)
  • Table 27 Europe: Companion Diagnostics Market Size, By Application, 2012-2019 ($Million) 88
  • Table 28 Europe: Market Size, By End User, 2012-2019 ($Million) 90
  • Table 29 Europe: Market Size For Pharmaceutical Companies, By Application, 2012-2019 ($Million)
  • Table 30 Europe: Market Size For Reference Laboratories, By Application, 2012-2019 ($Million)
  • Table 31 Europe: Market Size For Other End Users, By Application, 2012-2019 ($Million) 91
  • Table 32 Europe: Market Size, By Technology, 2012-2019 ($Million) 91
  • Table 33 Europe: Market Size For Pharmaceutical Companies, By Technology, 2012-2019 ($Million)
  • Table 34 Europe: Market Size For Reference Laboratories, By Technology, 2012-2019 ($Million)
  • Table 35 Europe: Market Size For Other End Users, By Technology, 2012-2019 ($Million) 92
  • Table 36 Asia: Companion Diagnostics Market Size, By Application, 2012-2019 ($Million) 95
  • Table 37 Asia: Market Size, By End Users, 2012-2019 ($Million) 95
  • Table 38 Asia: Market Size For Pharmaceutical Companies, By Application, 2012-2019 ($Million)
  • Table 39 Asia: Market Size For Reference Laboratories, By Application, 2012-2019 ($Million)
  • Table 40 Asia: Market Size For Other End Users, By Application, 2012-2019 ($Million) 96
  • Table 41 Asia: Market Size, By Technology, 2012-2019 ($Million) 97
  • Table 42 Asia: Market Size For Pharmaceutical Companies, By Technology, 2012-2019 ($Million)
  • Table 43 Asia: Market Size For Reference Laboratories, By Technology, 2012-2019 ($Million)
  • Table 44 Asia: Market Size For Other End Users, By Technology, 2012-2019 ($Million) 98
  • Table 45 Row: Companion Diagnostics Market Size, By Application, 2012-2019 ($Million) 99
  • Table 46 Row: Market Size, By End User, 2012-2019 ($Million) 99
  • Table 47 Row: Market Size For Pharmaceutical Companies, By Application, 2012-2019 ($Million)
  • Table 48 Row: Market Size For Reference Laboratories, By Application, 2012-2019 ($Million)
  • Table 49 Row: Market Size For Other End Users, By Application, 2012-2019 ($Million) 101
  • Table 50 Row: Market Size, By Technology, 2012-2019 ($Million) 101
  • Table 51 Row: Market Size For Pharmaceutical Companies, By Technology, 2012-2019 ($Million)
  • Table 52 Row: Market Size For Reference Laboratories, By Technology, 2012-2019 ($Million)
  • Table 53 Row: Market Size For Other End Users, By Technology, 2012-2019 ($Million) 102
  • Table 54 Agreements, Partnerships & Collaborations, 2011-2014
  • Table 55 Merger And Acquisitions, 2011-2014
  • Table 56 New Product Launch, 2011-2014
  • Table 57 Expansion, 2011-2014

List of Figures

  • Figure 1 Research Methodology
  • Figure 2 Bottom-Up Approach
  • Figure 3 Top-Down Approach
  • Figure 4 Break Down Of Primary Interviews: By Company Type, Designation, And Region
  • Figure 5 Cdx Technology Market Snapshot(2014 Vs 2019) : Ngs Market In Other Technology Is Expected To Grow Aggresively In Next Five Years.
  • Figure 6 Global Companion Diagnostics Market,By Application,2014
  • Figure 7 Market Share,2014
  • Figure 1 Attractive Market Opportunities In Global Market
  • Figure 2 Breast Cancer Segment Hold The Largest Market Share In Global Companion Diagnostic Market
  • Figure 3 Asia Is Expected To Commands Larger Share In Global Market
  • Figure 4 Global Companion Diagnostic Market, By Geography, 2014-2019
  • Figure 5 Global Companion Diagnostic Market, By Technology(2014-2019)
  • Figure 6 Asia Is Expected To Enter Exponential Growth Phase Market In Next 5 Years
  • Figure 7 New Approches Adopted By Leading Players
  • Figure 8 Technology Advancement Plays An Important Role In The Companion Diagnostic Market.
  • Figure 9 Market Segmentation :By Technology,Application And End-Users
  • Figure 10 Companion Diagnostic Gained Increasing Demand In The Oncology Segment
  • Figure 11 Porter's Five Forces Analysis
  • Figure 12 Strategic Benchmarking: Roche And Agilent Technologies, Inc. Largely Adopted Inorganic Growth Strategies For Technology Integration And Product Enhancement
  • Figure 13 Companion Diagnostics Applications Market Will Be Driven By Lung & Breast Cancer
  • Figure 14 Breast Cancer
  • Figure 15 Melanoma
  • Figure 16 End Users Of Companion Diagnostic Market
  • Figure 17 The Adoption Of Companion Diagnostic Is Significantly Growing Among Pharmaceutical Firms And Reference Laboratories
  • Figure 18 Pharmaceutical Companies In North America:Major End User Of Companion Diagnostic
  • Figure 19 Asia Is Expected To Be The Fastest-Growing Market For Companion Diagnostic
  • Figure 20 North America Driving The Global Market
  • Figure 21 Risingprevalence Of Life-Threatening Diseases To Drive Market Growth In North America
  • Figure 22 Europe Commands One-Third Of The Global Market
  • Figure 23 Companies Adopted Collaborations/Partnerships/Agreements As The Key Growth Strategy Over The Last Three Years
  • Figure 24 Battle For Market Share: Partnerships, Collaborations, Agreements Were Preferred Strategies
  • Figure 25 Geographic Revenue Mix Of Top 5 Market Players - Reference
  • Figure 26 Abbott Laboratories, Inc.: Business Overview
  • Figure 27 Agilent Technologies, Inc.: Business Overview
  • Figure 28 Swot Analysis
  • Figure 29 Biomeriux : Business Overview
  • Figure 30 Danaher Corporation : Business Overview
  • Figure 31 Ge Healthcare : Business Overview
  • Figure 32 Myriad Genetics : Business Overview
  • Figure 33 Qiagen N.V. : Business Overview
  • Figure 34 Swot Analysis
  • Figure 35 Roche Diagnostics: Business Overview
  • Figure 36 Thermo Fisher Scientific : Business Overview
Back to Top